159 related articles for article (PubMed ID: 8927870)
21. [Hormonal replacement therapy in women with metabolic disorders].
Bringer J; Lefebvre P
Contracept Fertil Sex; 1997 Oct; 25(10):757-60. PubMed ID: 9424214
[No Abstract] [Full Text] [Related]
22. Endocrine tumors.
van der Hoeven JJ; Pinedo HM
Cancer Chemother Biol Response Modif; 1988; 10():265-70. PubMed ID: 3079387
[No Abstract] [Full Text] [Related]
23. Cyclic nucleotide phosphodiesterases: critical modulators of endocrine, metabolic, and cardiovascular function and appealing therapeutic targets.
Manganiello V
Curr Opin Pharmacol; 2011 Dec; 11(6):646-8. PubMed ID: 22079477
[No Abstract] [Full Text] [Related]
24. Pharmacological chaperones: potential treatment for conformational diseases.
Bernier V; Lagacé M; Bichet DG; Bouvier M
Trends Endocrinol Metab; 2004 Jul; 15(5):222-8. PubMed ID: 15223052
[TBL] [Abstract][Full Text] [Related]
25. [Risk in metabolic diseases, endocrine diseases, hormonal therapy and in pregnancy].
Ries W
Stomatol DDR; 1980 Oct; 30(10):713-8. PubMed ID: 6936917
[No Abstract] [Full Text] [Related]
26. [Future of endocrinology: new concepts, new approaches, new treatments].
Touraine P; Beck-Peccoz P; Bertherat J; Brue T; Fève B; Rodien P
Ann Endocrinol (Paris); 2008 Apr; 69(2):97-8. PubMed ID: 18457683
[No Abstract] [Full Text] [Related]
27. [Hormone therapy].
Margolis MG; Mal'kovich VK
Med Sestra; 1979 Mar; 38(3):12-5. PubMed ID: 255196
[No Abstract] [Full Text] [Related]
28. Opinion and evidence for treatments in endocrine disorders.
Treat Endocrinol; 2002; 1(6):415-9. PubMed ID: 15832494
[TBL] [Abstract][Full Text] [Related]
29. [Current therapeutic developments].
van Cauwenberge H; Luyckx A
Rev Med Liege; 1979 May; 34(9):413-20. PubMed ID: 472582
[No Abstract] [Full Text] [Related]
30. [Hormone replacement Up-to-date. Effect of estrogen therapy (EP) and estrogen-progestogen therapy (EPT) on the bone metabolism].
Taniguchi R; Higuchi T; Mizunuma H
Clin Calcium; 2007 Sep; 17(9):1342-8. PubMed ID: 17767022
[TBL] [Abstract][Full Text] [Related]
31. Unraveling the intricacies of receptor activated cell signaling and transcriptional cascades enhance opportunities to develop new therapeutic targets for endocrine and metabolic diseases.
Firestone GL
Curr Opin Pharmacol; 2010 Dec; 10(6):607-12. PubMed ID: 21036104
[No Abstract] [Full Text] [Related]
32. Endocrine emergencies.
Daggett P
Br J Hosp Med; 1979 Jan; 21(1):38-44. PubMed ID: 435667
[TBL] [Abstract][Full Text] [Related]
33. Pharmacotherapeutic uses of hormones.
Hyman P; Kelner P
Nurs Clin North Am; 2007 Mar; 42(1):1-18, v. PubMed ID: 17270586
[TBL] [Abstract][Full Text] [Related]
34. [Problems of specificity in endocrine psychopharmacology].
Semen-Negrea E; Almăjan E
Stud Cercet Endocrinol; 1967; 18(1):21-33. PubMed ID: 5343249
[No Abstract] [Full Text] [Related]
35. Raloxifene and prevention of vertebral fracture (cont'd): mainly when oestrogen is contraindicated.
Prescrire Int; 2000 Dec; 9(50):190-1. PubMed ID: 11475503
[TBL] [Abstract][Full Text] [Related]
36. A report from the endocrine society's 94th annual meeting & expo (June 23-26 - Houston, Texas, USA).
Rabasseda X
Drugs Today (Barc); 2012 Sep; 48(9):615-25. PubMed ID: 23032802
[TBL] [Abstract][Full Text] [Related]
37. [Therapeutic news of 1975].
Luyckx A; Van Cauwenberge H
Rev Med Liege; 1976 Apr; 31(8):267-80. PubMed ID: 13473
[No Abstract] [Full Text] [Related]
38. [Hormone resistance in the tissues].
Daniel K
Postepy Hig Med Dosw; 1982; 36(1-3):1-33. PubMed ID: 6306624
[No Abstract] [Full Text] [Related]
39. Menopausal hormone replacement therapy and risk of breast cancer. Implications for the treatment of osteoporosis in postmenopausal women.
Lopes P
Rev Rhum Engl Ed; 1996 May; 63(5):309-11. PubMed ID: 8789875
[No Abstract] [Full Text] [Related]
40. [Hormone replacement therapy of postmenopausal osteoporosis].
Lin S
Zhonghua Yi Xue Za Zhi; 1992 May; 72(5):313-4. PubMed ID: 1327464
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
